1. Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells. Issue 1 (December 2016) Authors: Halbach, Sebastian; Hu, Zehan; Gretzmeier, Christine; Ellermann, Julia; Wöhrle, Franziska; Dengjel, Jörn; Brummer, Tilman Journal: Cell communication and signaling Issue: Volume 14:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DGfI Study Group Vaccines ‐ Annual Meeting 2022. Issue 3 (23rd February 2022) Authors: Wöhrle, Franziska; Kerscher, Bernhard; Cicin‐Sain, Luka; Bekeredjian‐Ding, Isabelle Journal: European journal of immunology Issue: Volume 52:Issue 3(2022) Page Start: 370 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗